GlaxoSmithKline PLC
OTC:GLAXF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
GlaxoSmithKline PLC (GLAXF) under the Base Case is 23.19 USD per share.
Compared with the current market price of 23.4 USD, the stock appears
Overvalued by 1% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What GlaxoSmithKline Does
GlaxoSmithKline, or GSK, is a global drug maker focused on prescription medicines and vaccines. It develops and sells treatments for areas such as respiratory disease, HIV, immunology, oncology, and infectious disease, along with vaccines for children, adults, and travel-related prevention. Its main customers are governments, health systems, hospitals, doctors, and pharmacies that buy and distribute its products to patients.
- Headquarters
- United Kingdom UK
- Employees
- 90 096
- IPO date
- May 22, 1972
GlaxoSmithKline has no economic moat
Protection rests on individual medicines rather than a lasting barrier around GSK as a whole: patents protect particular drugs, while competing treatments can still reach customers. Generic competition in established medicines shows why successful products do not guarantee lasting protection across the business.
Read the full moat analysisBalance Sheet
Recent Events
Latest Earnings Call
GSK reconfirmed its 2026 outlook as specialty-led momentum continued, while management highlighted pipeline expansion and ongoing launch, vaccine-market and HIV-development uncertainties.
Open the earnings call- EPS
- GBX 0.55
- Expected
- GBX 0.53
- Surprise
- +3.0%
- Stock, next trading day
- −1.0%
Past 12 months
Continue GLAXF Research
Decided on GlaxoSmithKline? Get an email when GLAXF reaches the price you’d buy at. Free with an account.
Other GlaxoSmithKline listings
What is the Intrinsic Value of one GLAXF stock?
The intrinsic value for
GlaxoSmithKline PLC (GLAXF) under the Base Case is 23.19 USD.
Is GLAXF stock undervalued or overvalued?
Compared with the current market price of 23.4 USD, the stock appears Overvalued by 1% .